GBIO - Generation Bio Co.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
GBIO price evolution
GBIO
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $30.65 | $37.71 | $72.24 | |
| Short term investments | $188.44 | $183.78 | $197.92 | |
| Net receivables | $2.21 | $1.34 | $3.96 | |
| Inventory | ||||
| Total current assets | $191.25 | $223.28 | $226.85 | $272.62 |
| Long term investments | $16.79 | |||
| Property, plant & equipment | $37.23 | $39.2 | $41.56 | $95.65 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $41.98 | $59.03 | $102.14 | |
| Total investments | $188.44 | $200.56 | $197.92 | |
| Total assets | $248.78 | $265.26 | $285.88 | $374.76 |
| Current liabilities | ||||
| Accounts payable | $1.66 | $1.91 | $1.48 | $2.35 |
| Deferred revenue | $48.05 | $50.8 | $54.86 | |
| Short long term debt | $8.63 | $8.37 | $8.12 | |
| Total current liabilities | $30.16 | $30.1 | $28.31 | $39.91 |
| Long term debt | $85.32 | $87.58 | $89.77 | |
| Total noncurrent liabilities | $119.75 | $125.58 | $131.72 | |
| Total debt | $93.96 | $95.94 | $97.89 | |
| Total liabilities | $144.34 | $149.86 | $153.89 | $171.63 |
| Shareholders' equity | ||||
| Retained earnings | -$681.66 | -$666.35 | -$645.92 | -$571.38 |
| Other shareholder equity | $0.32 | -$0.28 | -$0.2 | $0.27 |
| Total shareholder equity | $115.41 | $131.99 | $203.13 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $72.24 | $98.86 | $380.84 | $62.89 |
| Short term investments | $197.92 | $185.92 | $199.44 | |
| Net receivables | $3.96 | $0.4 | ||
| Inventory | ||||
| Total current assets | $272.62 | $287.02 | $379.19 | $267.74 |
| Long term investments | ||||
| Property, plant & equipment | $95.65 | $81.42 | $91.03 | $23.78 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $102.14 | $89.25 | $97.58 | $26.42 |
| Total investments | $197.92 | $185.92 | $199.44 | |
| Total assets | $374.76 | $376.26 | $476.77 | $294.15 |
| Current liabilities | ||||
| Accounts payable | $2.35 | $0.66 | $2.02 | $0.27 |
| Deferred revenue | $54.86 | |||
| Short long term debt | $8.12 | $7.09 | $4.61 | |
| Total current liabilities | $39.91 | $19.15 | $18.81 | $11.22 |
| Long term debt | $89.77 | $74.62 | $76.22 | |
| Total noncurrent liabilities | $131.72 | $74.62 | $76.22 | $14.92 |
| Total debt | $97.89 | $81.71 | $80.83 | |
| Total liabilities | $171.63 | $93.77 | $95.03 | $26.14 |
| Shareholders' equity | ||||
| Retained earnings | -$571.38 | -$444.76 | -$308.13 | -$188.97 |
| Other shareholder equity | $0.27 | -$0.08 | $0.01 | |
| Total shareholder equity | $203.13 | $282.49 | $381.75 | $268.01 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $7.55 | $4.09 | $4.06 | $2.88 |
| Cost of revenue | ||||
| Gross Profit | $4.09 | $4.06 | $2.88 | |
| Operating activities | ||||
| Research & development | $16.39 | $14.34 | $27.92 | |
| Selling, general & administrative | $9.52 | $10.43 | $13.38 | |
| Total operating expenses | $24.27 | $27.4 | $81.69 | $41.3 |
| Operating income | -$23.31 | -$77.63 | -$38.42 | |
| Income from continuing operations | ||||
| EBIT | -$20.43 | -$74.54 | -$35.19 | |
| Income tax expense | ||||
| Interest expense | $2.57 | |||
| Net income | ||||
| Net income | -$15.31 | -$20.43 | -$74.54 | -$35.19 |
| Income (for common shares) | -$20.43 | -$74.54 | -$35.19 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $5.9 | |||
| Cost of revenue | ||||
| Gross Profit | $5.9 | |||
| Operating activities | ||||
| Research & development | $93.62 | $96.72 | $85.25 | $58.53 |
| Selling, general & administrative | $50.85 | $44.46 | $33.85 | $22.58 |
| Total operating expenses | $144.47 | $141.18 | $119.1 | $81.11 |
| Operating income | -$138.56 | -$141.18 | -$119.1 | -$81.11 |
| Income from continuing operations | ||||
| EBIT | -$126.61 | -$136.64 | -$119.15 | -$80.52 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$126.61 | -$136.64 | -$119.15 | -$80.52 |
| Income (for common shares) | -$126.61 | -$136.64 | -$119.15 | -$80.52 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$20.43 | -$74.54 | -$35.19 | |
| Operating activities | ||||
| Depreciation | $1.26 | $1.31 | $1.32 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $3.7 | $4 | $6.05 | |
| Total cash flows from operations | -$21.54 | -$31.7 | -$24.98 | |
| Investing activities | ||||
| Capital expenditures | $0.09 | -$1.92 | -$4.58 | |
| Investments | $12 | $1.36 | $2.67 | |
| Total cash flows from investing | $24.25 | $12.09 | -$0.55 | -$1.91 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.27 | $0.18 | ||
| Net borrowings | ||||
| Total cash flows from financing | $0.11 | $0.23 | -$0.13 | $0.08 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$48.43 | -$9.21 | -$32.38 | -$26.82 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$126.61 | -$136.64 | -$119.15 | -$80.52 |
| Operating activities | ||||
| Depreciation | $5.26 | $5.13 | $4.53 | $3.43 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $24.34 | $24.45 | $17.86 | $8.41 |
| Total cash flows from operations | -$52.74 | -$102.45 | -$91.82 | -$70.14 |
| Investing activities | ||||
| Capital expenditures | -$7.4 | -$8.8 | -$5.85 | -$5.52 |
| Investments | -$2.3 | -$183.71 | $198.9 | -$199.68 |
| Total cash flows from investing | -$9.7 | -$192.51 | $193.05 | -$205.2 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $36.55 | $13.62 | $215.63 | $214.28 |
| Net borrowings | ||||
| Total cash flows from financing | $35.82 | $12.99 | $214.67 | $323.1 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$26.63 | -$281.97 | $315.9 | $47.76 |
News
Fundamentals
| Market cap | $411.87M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 66.75M |
| Revenue | $18.58M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$145.47M |
| Revenue Q/Q | 252.00% |
| Revenue Y/Y | N/A |
| P/E ratio | -2.83 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 22.16 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$2.18 |
|---|---|
| ROA | -49.54% |
| ROE | N/A |
| Debt/Equity | 0.84 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 6.34 |
| Quick ratio | N/A |